Cargando…

Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yaewon, Im, Seock-Ah, Keam, Bhumsuk, Lee, Kyung‑Hun, Kim, Tae‑Yong, Suh, Koung Jin, Ryu, Han Suk, Moon, Hyeong-Gon, Han, Sae‑Won, Oh, Do‑Youn, Han, Wonshik, Kim, Tae‑You, Park, In Ae, Noh, Dong-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955253/ https://www.ncbi.nlm.nih.gov/pubmed/27444430 http://dx.doi.org/10.1186/s12885-016-2500-1

Ejemplares similares

Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review
por: Kim, Miso, et al.
Publicado: (2014)

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
por: Beom, Seung Hoon, et al.
Publicado: (2017)

Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
por: Lee, Kyung-Hun, et al.
Publicado: (2012)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Keam, Bhumsuk, et al.
Publicado: (2011)

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
por: Kim, Hee-Jun, et al.
Publicado: (2015)

Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients
por: Yang, Yaewon, et al.
Publicado: (2020)

Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy
por: Kim, Min Kyoon, et al.
Publicado: (2015)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Kim, Taeryung, et al.
Publicado: (2015)

Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Han, Ahram, et al.
Publicado: (2013)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response
por: Lee, Ho-chang, et al.
Publicado: (2013)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment
por: Yoo, Tae-Kyung, et al.
Publicado: (2017)

Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2019)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini’s Mean Difference of Restricted Mean Survival Times
por: Keam, Bhumsuk, et al.
Publicado: (2021)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients
por: Choi, Mihong, et al.
Publicado: (2021)

Correction: Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

Reduced proliferation in breast cancer cells contacting the neighboring adipocytes in human breast cancer tissues
por: Ryu, Han Suk, et al.
Publicado: (2015)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Perspective Insight into Future Potential Fusion Gene Transcript Biomarker Candidates in Breast Cancer
por: Kim, Ryong Nam, et al.
Publicado: (2018)

Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis
por: Shin, Hee-Chul, et al.
Publicado: (2016)

Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis
por: Yoo, Tae-Kyung, et al.
Publicado: (2018)

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
por: Suh, Koung Jin, et al.
Publicado: (2017)

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions
por: Kim, Tae-Yong, et al.
Publicado: (2014)

Intensity of metastasis screening and survival outcomes in patients with breast cancer
por: Cheun, Jong-Ho, et al.
Publicado: (2021)

Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer
por: Yoo, Tae-Kyung, et al.
Publicado: (2016)

Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy
por: Shin, Jae Jun, et al.
Publicado: (2019)

Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer
por: Hwang, Ki-Tae, et al.
Publicado: (2017)

The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers
por: Moon, Hyeong-Gon, et al.
Publicado: (2015)

Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism
por: Lee, Jiwoo, et al.
Publicado: (2017)

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)

A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer
por: Kim, Yumi, et al.
Publicado: (2019)

Erratum: A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer
por: Kim, Yumi, et al.
Publicado: (2020)

Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer
por: Moon, Hyeong-Gon, et al.
Publicado: (2012)

Life-Threatening Hematoma in an Elderly Breast Cancer Patient Undergoing Chemotherapy
por: Shin, Ik Beom, et al.
Publicado: (2023)

Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
por: Shin, Jae Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5vmptffpnsm0npkrsk4h33hf0l